AQST (Aquestive Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by AQST officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-10 | Peter E. Boyd | Chief People Officer | X | — | — |
| 2026-09-09 | Daniel Barber | President and CEO | X | — | — |
| 2026-09-08 | Cassie Jung | Chief Operating Officer | X | — | — |
| 2026-08-18 | Daniel Barber | President and CEO | Sell | — | — |
| 2026-08-17 | Sherry Korczynski | Chief Commercial Officer | F | — | — |
| 2026-07-17 | Daniel Barber | President and CEO | Sell | — | — |
| 2026-06-24 | Julie Krop | Director | MIXED | — | — |
| 2026-06-16 | Daniel Barber | President and CEO | Sell | — | — |
| 2026-06-12 | Marco Taglietti | Director | A | — | — |
| 2026-06-12 | Abigail L. Jenkins | Director | A | — | — |
| 2026-06-12 | Julie Krop | Director | A | — | — |
| 2026-06-12 | TIMOTHY E MORRIS | Director | A | — | — |
| 2026-06-12 | John Cochran | Director | A | — | — |
| 2026-06-12 | GREGORY B BROWN | Director | A | — | — |
| 2026-06-09 | Sherry Korczynski | Chief Commercial Officer | F | — | — |
| 2026-05-19 | Thomas A. Zalewski | Chief Legal Officer | A | — | — |
| 2026-05-18 | Melina Cioffi | SVP, Regulatory Affairs | F | — | — |
| 2026-05-18 | Daniel Barber | President and CEO | Sell | — | — |
| 2026-05-11 | LORI J BRAENDER | Corporate Secretary | F | — | — |
| 2026-05-07 | Daniel Barber | President and CEO | F | — | — |
| 2026-05-07 | LORI J BRAENDER | Corporate Secretary | F | — | — |
| 2026-05-07 | Cassie Jung | Chief Operating Officer | F | — | — |
| 2026-05-07 | A ERNEST TOTH JR | Chief Financial Officer | F | — | — |
| 2026-05-07 | Peter E. Boyd | Chief People Officer | F | — | — |
| 2026-04-13 | Sherry Korczynski | Chief Commercial Officer | A | — | — |
| 2026-04-13 | Cassie Jung | Chief Operating Officer | A | — | — |
| 2026-04-13 | LORI J BRAENDER | Corporate Secretary | A | — | — |
| 2026-04-13 | Daniel Barber | President and CEO | A | — | — |
| 2026-04-13 | A ERNEST TOTH JR | SVP, Chief Financial Officer | A | — | — |
| 2026-04-13 | Peter E. Boyd | Chief People Officer | A | — | — |
| 2026-03-11 | Melina Cioffi | SVP, Regulatory Affairs | MIXED | — | — |
| 2026-03-11 | Matthew W. Davis | Chief Development Officer | A | — | — |
| 2026-03-11 | Peter E. Boyd | Chief People Officer | MIXED | — | — |
| 2026-03-11 | LORI J BRAENDER | Chief Legal Officer | MIXED | — | — |
| 2026-03-11 | Cassie Jung | Chief Operating Officer | MIXED | — | — |
| 2026-03-11 | A ERNEST TOTH JR | Chief Financial Officer | MIXED | — | — |
| 2026-03-11 | Daniel Barber | President and CEO | MIXED | — | — |
| 2026-03-11 | Sherry Korczynski | Chief Commercial Officer | MIXED | — | — |
| 2026-03-11 | Matthew J. Greenhawt | Chief Medical Officer | A | — | — |
| 2025-12-05 | Peter E. Boyd | Chief People Officer | A | — | — |
| 2025-12-04 | Melina Cioffi | SVP, Regulatory Affairs | F | — | — |
| 2025-11-12 | Matthew W. Davis | Chief Development Officer | A | — | — |
| 2025-10-17 | Carl N Kraus | Chief Medical Officer | Sell | — | — |
| 2025-10-17 | Cassie Jung | Chief Operating Officer | MIXED | — | — |
| 2025-10-17 | Peter E. Boyd | See Remarks | Sell | — | — |
| 2025-09-29 | Peter E. Boyd | See Remarks | Sell | — | — |
| 2025-09-29 | Daniel Barber | President and CEO | Sell | — | — |
| 2025-09-22 | Daniel Barber | President and CEO | Sell | — | — |
| 2025-09-08 | Peter E. Boyd | See Remarks | Sell | — | — |
| 2025-09-08 | Cassie Jung | Chief Operating Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 3,481,332 | — |
| — | 10%+ Owner | 2,324,162 | — |
| — | Chief Innovation/Tech Officer | 980,726 | — |
| — | President and CEO | 677,317 | — |
| — | CEO and President | 637,149 | — |
| — | Chief Science Officer | 363,555 | — |
| — | Chief Financial Officer | 283,460 | — |
| — | Chief Medical Officer | 282,475 | — |
| — | Chief People Officer | 281,731 | — |
| — | SVP, Regulatory Affairs | 273,200 | — |
| — | Chief Commercial Officer | 235,689 | — |
| — | Corporate Secretary | 231,042 | — |
| — | Chief Operating Officer | 208,833 | — |
| — | SVP, Chief Commercial Officer | 151,445 | — |
| — | SVP-Chief Financial Officer | 150,614 | — |
| — | Chief Development Officer | 100,000 | — |
| — | Chief Legal Officer | 100,000 | — |
| — | Director | 99,486 | — |
| — | SVP-HR and Org. Development | 80,765 | — |
| — | Chief Medical Officer | 77,000 | — |
| — | Director | 75,085 | — |
| — | Director | 59,636 | — |
| — | Director | 31,635 | — |
| — | Director | 17,327 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AQST quote page; the site-wide leaderboard is on the insider transactions hub.